Advertisement

The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes: A Cluster Randomized Trial-based Economic Evaluation

Published:December 09, 2022DOI:https://doi.org/10.1016/j.jval.2022.11.021

      Highlights

      • There is evidence that contingency management (CM) may be an effective strategy in heroin treatment; nevertheless, there is limited evidence of cost-effectiveness.
      • CM is not a cost-effective strategy for promoting heroin abstinence and treatment engagement in England.
      • Further research into the duration and the target of incentives is needed before CM could be considered value for money in English drug treatment services.

      Abstract

      Objectives

      Cost-effectiveness analysis of two 12-week contingency management (CM) schedules targeting heroin abstinence or attendance at weekly keyworker appointments for opioid agonist treatment compared with treatment as usual (TAU).

      Methods

      A cost-effectiveness analysis was conducted alongside a cluster randomized trial of 552 patients from 34 clusters (drug treatment clinics) randomly allocated 1:1:1 to opioid agonist treatment plus weekly keyworker appointments with (1) CM targeted at heroin abstinence (CM abstinence), (2) CM targeted at on-time attendance at weekly appointments (CM attendance), or (3) no CM (TAU). The primary cost-effectiveness analysis at 24 weeks after randomization took a societal cost perspective with effects measured in heroin-negative urine samples.

      Results

      At 24 weeks, mean differences in weekly heroin-negative urine results compared with TAU were 0.252 (95% confidence interval [CI] −0.397 to 0.901) for CM abstinence and 0.089 (95% CI −0.223 to 0.402) for CM attendance. Mean differences in costs were £2562 (95% CI £32-£5092) for CM abstinence and £317 (95% CI −£882 to £1518) for CM attendance. Incremental cost-effectiveness ratios were £10 167 per additional heroin-free urine for CM abstinence and £3562 for CM attendance with low probabilities of cost-effectiveness of 3.5% and 36%, respectively. Results were sensitive to timing of follow-up for CM attendance, which dominated TAU (better outcomes, lower costs) at 12 weeks, with an 88.4% probability of being cost-effective. Probability of cost-effectiveness remained low for CM abstinence (8.6%).

      Conclusions

      Financial incentives targeted toward heroin abstinence and treatment attendance were not cost-effective over the 24-week follow-up. Nevertheless, CM attendance was cost-effective over the treatment period (12 weeks), when participants were receiving keyworker appointments and incentives.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Value in Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Deaths related to drug poisoning in England and Wales: 2021 registrations. Office for National Statistics.
        (Accessed January 10, 2023)
        • Jalali M.S.
        • Botticelli M.
        • Hwang R.C.
        • Koh H.K.
        • McHugh R.K.
        The opioid crisis: a contextual, social-ecological framework.
        Health Res Policy Syst. 2020; 18: 87
        • Gordon L.
        • Tinsley L.
        • Godfrey C.
        • et al.
        The economic and social costs of class A drug use in England and Wales 2003/04.
        in: Singleton N. Murray R. Tinsley L. Measuring Different Aspects of Problem Drug Use: Methodological Developments. Online Report 16/06. 2nd ed. Home Office, London, United Kingdom2006
        • Godfrey C.
        • Eaton G.
        • McDougall C.
        • et al.
        The economic and social costs of class A drug use in England and Wales, 2000. Health Research Board.
        (Accessed January 10, 2023)
      2. Methadone and buprenorphine for the management of opioid dependence. National Institute for Health and Care Excellence.
        (Accessed January 10, 2023)
        • Onuoha E.N.
        • Leff J.A.
        • Schackman B.R.
        • McCollister K.E.
        • Polsky D.
        • Murphy S.M.
        Economic evaluations of pharmacologic treatment for opioid use disorder: a systematic literature review.
        Value Health. 2021; 24: 1068-1083
      3. Drug misuse - psychosocial interventions. National Institute for Health and Care Excellence.
        (Accessed January 10, 2023)
        • Shearer J.
        • Tie H.
        • Byford S.
        Economic evaluations of contingency management in illicit drug misuse programmes: a systematic review.
        Drug Alcohol Rev. 2015; 34: 289-298
        • Metrebian N.
        • Weaver T.
        • Goldsmith K.
        • et al.
        Using a pragmatically adapted, low-cost, contingency management intervention to promote heroin abstinence in individuals undergoing treatment for heroin use disorder in UK drug services (PRAISE): a cluster randomised trial.
        BMJ open. 2021; 11e046371
        • Metrebian N.
        • Weaver T.
        • Pilling S.
        • et al.
        Positive Reinforcement targeting Abstinence in Substance misuse (PRAISe): cluster RCT & Process Evaluation of Contingency Management.
        Contemp Clin Trials. 2018; 71: 124-132
        • Byford S.
        • Barrett B.
        • Metrebian N.
        • et al.
        Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction.
        Br J Psychiatry. 2013; 203: 341-349
      4. The guidelines manual. Process and methods. PMG6. National Institute for Health and Care Excellence.
        • Kind P.
        The EuroQol instrument: an index of health related quality of life.
        in: Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Lippincott-Raven, Philadelphia, PA1996
        • van der Zanden B.P.
        • Dijkgraaf M.G.
        • Blanken P.
        • de Borgie C.A.
        • van Ree J.M.
        • van den Brink W.
        Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population.
        Drug Alcohol Depend. 2006; 82: 111-118
        • Dolan P.
        Modeling valuations for EuroQol health states.
        Med Care. 1997; 35: 1095-1108
        • Richardson G.
        • Manca A.
        Calculation of quality adjusted life years in the published literature: a review of methodology and transparency.
        Health Econ. 2004; 13: 1203-1210
        • Kessler R.
        • Barber C.
        • Beck A.
        • et al.
        The World Health Organization Health and Work Performance Questionnaire (HPQ).
        J Occup Environ Med. 2003; 45: 156-174
        • Curtis L.
        • Burns A.
        PSSRU unit costs of health and social care 2015. Personal Social Services Research Unit.
        (Accessed January 10, 2023)
      5. NHS prescription services. NHS.
        • Drummond M.
        • Sculpher M.
        • Claxton K.
        • et al.
        Methods for the Economic Evaluation of Health Care Programmes.
        4th ed. Oxford University Press, Oxford, United Kingdom2015
        • Marsden J.
        • Stillwell G.
        • James J.
        • et al.
        Effectiveness and cost-effectiveness of adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial.
        Lancet Psychiatry. 2019; 6: 391-402
        • Dubourg R.
        • Hamed J.
        The economic and social costs of crime against individuals and households 2003/04. Estimates of the economic and social costs of crime in England and Wales: costs of crime against individuals and households, 2003/04. Home Office.
        (Accessed January 10, 2023)
        • Brand S.
        • Price R.
        The economic and social costs of crime. Home Office Research Studies.
        (Accessed January 10, 2023)
        • Mihaylova B.
        • Briggs A.
        • O’Hagan A.
        • Thompson S.G.
        Review of statistical methods for analysing healthcare resources and costs.
        Health Econ. 2011; 20: 897-916
        • White I.R.
        • Royston P.
        • Wood A.M.
        Multiple imputation using chained equations: issues and guidance for practice.
        Stat Med. 2011; 30: 377-399
        • Eddings W.
        • Marchenko Y.
        Accounting for Clustering With Mi Impute.
        StataCorp LP, College Station, TX2016
        • Schomaker M.
        • Heumann C.
        Bootstrap inference when using multiple imputation.
        Stat Med. 2018; 37: 2252-2266
        • Barber J.A.
        • Thompson S.G.
        Analysis of cost data in randomized trials: an application of the non-parametric bootstrap.
        Stat Med. 2000; 19: 3219-3236
        • Fenwick E.
        • Claxton K.
        • Sculpher M.
        Representing uncertainty: the role of cost-effectiveness acceptability curves.
        Health Econ. 2001; 10: 779-787
      6. NICE health technology evaluations: the manual (PMG36): process and methods. National Institute for Health and Care Excellence.
        (Accessed January 10, 2023)
        • Robertson R.
        • Baylis A.
        • Buck D.
        • Fenney D.
        • Ross S.
        Improving drug treatment services in England. The King’s Fund.
        (Accessed January 10, 2023)
        • Stitzer M.
        Editorial: contingency management and the addictions.
        Addiction. 2006; 101: 1536-1537
        • Volkov N.D.
        The epidemic of fentanyl misuse and overdoses: challenges and strategies.
        World Psychiatry. 2021; 20: 195-196
        • Davis D.R.
        • Kurti A.N.
        • Skelly J.M.
        • Redner R.
        • White T.J.
        • Higgins S.T.
        A review of the literature on contingency management in the treatment of substance misuse disorders 2009-2014.
        Prev Med. 2016; 92: 36-46
      7. Drug misuse and dependence: UK guidelines on clinical management. Department of Health.
        (Accessed January 10, 2023)
        • Walker M.
        Self-reported crime studies and the British crime survey.
        Howard J Crime Justice. 1983; 22: 168-176
        • Darke S.
        Self-report among injecting drug users: a review.
        Drug Alcohol Depend. 1998; 51: 253-263
        • El Alili M.
        • van Dongen J.
        • Goldfeld K.
        • Heymans M.
        • van Tulder M.
        • Bosmans J.
        Taking the analysis of trial-based economic evaluations to the next level: the importance of accounting for clustering.
        Pharmacoeconomics. 2020; 38: 1247-1261